Background Hand dexterity impairment is a key feature of disability in people with primary progressive multiple sclerosis (PPMS). So far, ocrelizumab, a recombinant humanized monoclonal antibody that selectively depletes CD20-expressing B cells, is the only therapy approved for PPMS and recent analysis reported its ability to reduce the risk of...
-
2022 (v1)PublicationUploaded on: February 14, 2024
-
2023 (v1)Publication
IntroductionThe subventricular zone (SVZ) represents one of the main adult brain neurogenesis niche. In-vivo imaging of SVZ is very challenging and little is known about MRI correlates of SVZ macro- and micro-structural injury in multiple sclerosis (MS) patients. MethodsThe aim of the present study is to evaluate differences in terms of volume...
Uploaded on: February 14, 2024